The HAI diagnostics market size is projected to cross $4.3 billion by 2023, growing at a CAGR of 7.6% between 2017-2023.
In terms of application, the HAI diagnostics market is segmented into drug-resistance testing and disease testing. The drug-resistance testing held the larger share in the market in 2016, owing to the modernization in molecular diagnostics that has enabled drug-resistance testing. With the development of novel testing techniques such as phenotypic resistance testing, hybridization methods, sample processing and sequencing the diagnosis rate has increased to may folds and is expected to grow in near future.
Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/hospital-acquired-infection-diagnostics-market/report-sample
The European HAI diagnostics market is projected to grow at a steady pace during 2017-2023, to cross $1.2 billion by 2023. According to the International Trade Administration (ITA), there is growth in the market, with the major companies such as Roche Diagnostics Limited, Abbott Laboratories, and others investing more in the R&D of the innovative diagnostics products to remain competitive in this field. Along with it, the growth of the hospital acquired diagnostics market in Europe is also characterized by the increase in geriatric population and high incidence of hospital acquired infections.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hospital-acquired-infection-diagnostics-market
Technologically advanced products aid by offering accurate and reliable results with low turnaround time. Major companies in the HAI diagnostics market are investing in the development of the molecular diagnostics, looking forward to the growth and demand in the field. For instance, Roche diagnostics, in 2017, launched cobas Liat PCR system with four assays, which also include 20-minute real-time PCR nucleic acid test to detect Clostridium difficile. The company also launched cobas HPV for using on cobas 6800/8800 system for cervical cancer screening, 2017. Cobas 6800/8800 system is a two integrated and fully automated molecular testing system for blood and plasma donor screening. Qiagen N.V., in 2017, launched ipsogen JAK2 RGQ PCR Kit for detection of blood cancer, ipsogen portfolios common, and rare leukemia types.
Some of the key players operating in the HAI diagnostics market are Abbott Laboratories, AstraZeneca plc, Bayer AG, Daiichi Sankyo Co. Ltd., Danaher Corporation, Hologic Inc., Johnson & Johnson, OpGen Inc., and F. Hoffmann-La Roche AG.
Contact:
P&S Intelligence
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
According to the latest market report published by Research Report Insights, titled ‘Global Hospital Acquired Infections ControlMarket’: Industry Analysis 2012-2016and Forecast2017-2025. The global hospital acquired infections control market is expected to expand at a CAGR of 4.8% during the forecast period 2017-2025.
The market is segmented based on product type, end user, and region.
Report For Report Sample with Table of Contents@https://www.researchreportinsights.com/report/sample/110114926/Hospital-Acquired-Infections-Control-Market
On the basis of product type, market has been segmented as heat sterilization equipment (moist heat sterilization equipment and dry heat sterilization equipment), low temperature sterilization equipment, radiation sterilization equipment, and disinfection equipment (disinfector (washer disinfector and flusher disinfector), endoscopic reprocessor systems (single basin endoscopic reprocessor systems and dual basin endoscopic reprocessor systems), and disinfectants). Among these segments, disinfection equipment segment is expected to register the highest market share of 50.8% in 2025 and expand at a CAGR of 5.1% in terms of revenue between 2017 and 2025.
On the basis of end users, market has been segmented as hospitals, ambulatory surgical centers, medical institutions, diagnostic laboratories, and clinics. The hospital end use segment contributed the leading shares, and the trend is expected to continue over the forecast period. Hospitals end use segment hold the market share of 32.0% in 2017, and expand at a CAGR of 4.7 % in terms of revenue between 2017 and 2025. Followed by hospitals, ambulatory surgical centers end use segment holds the significant market share in terms of revenue over the forecast period.
Request For Report Discount@https://www.researchreportinsights.com/report/discount/110114926/Hospital-Acquired-Infections-Control-Market
By region, the global hospital acquired infections controlmarket has been segmented into North America, Latin America, Europe, Asia Pacific (APAC), and Middle East & Africa (MEA).Globally, in terms of revenue, North America has been anticipated to account for the highest share of 39.5% in 2017 and expand at a CAGR of 4.2% in terms of revenue between 2017 and 2025, followed by Europe. Meanwhile, revenue from the market in Asia Pacific (APAC) is expected to expand at the significant CAGR of 5.7% over the forecast period.
The global hospital acquired infections control market shows a healthy growth over the forecast period. The factor such as shifting of healthcare model towards value-based model, increasing spending on healthcare per capita & increasing industry consolidation, and growth in emerging markets coupled with pricing pressure on the manufacturers are fueling the growth of hospital acquired infections control market. Changing demographics in the emerging economies like China, India, Brazil and South Africa is expected to provide high growth opportunities for medical device manufacturers. Public and private healthcare expenditure in these countries is expected to witness high growth which in turn is expected to drive focus of the manufacturers in these markets. In addition, increasing out-of-pocket healthcare expenditure in both developing and developed economies is expected to fuel demand for advanced endoscopy surgical procedures and thus, increase use of automated endoscope reprocessors in various healthcare sectors.
Furthermore, expanding number of hospital mergers and unions are relied upon to have wild effect on the restorative medical device producers attributable to huge number of doctor's facility arrange working under one association, these systems can influence the cost of the AERs with the makers and thus diminishing their gainfulness edges. Large patient pool & rise in disposable income coupled with increase in number of hospitals in emerging economies, and development & advancements in reprocessing in developed economies are few factor are also gardening the market growth of hospital acquired infections control.
Some of the key players in the global hospital acquired infections control market includes Olympus Corporation, Medivators Inc. (Cantel Medical Corp.), Getinge Group, STERIS Plc., Belimed AG (Metall Zug), Steelco S.P.A, Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Advanced Sterilization Products Services Inc. (Johnson & Johnson), Abbott Laboratories, Bayer AG, Alere Inc., The 3M Company, and Cepheid Inc.
Report Analysis@https://www.researchreportinsights.com/report/rd/110114926/Hospital-Acquired-Infections-Control-Market
Theglobal hospital acquired infections control marketis segmented as follows:
By Product Type
• Heat Sterilization Equipment
? Moist Heat Sterilization Equipment
? Dry Heat Sterilization Equipment
• Low Temperature Sterilization Equipment
• Radiation Sterilization Equipment
• Disinfection Equipment
• Disinfector
• Washer Disinfector
• Flusher Disinfector
• Endoscopic Reprocessor Systems
• Single Basin Endoscopic Reprocessor Systems
• Dual Basin Endoscopic Reprocessor Systems
• Disinfectants
By End User
• Hospitals
• Ambulatory Surgical Centers
• Medical Institutions
• Diagnostic Laboratories
• Clinics
By Region
• North America
• Latin America
• Europe
• Asia-Pacific
• Middle East & Africa
